News Chart Monte Rosa Therapeutics, Inc.

Stocks

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq 23:00:00 04/09/2026 +03			5-day change	1st Jan Change
13.84 ^USD	-3.76%		+3.44%	-11.73%

08-24	Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study	MT
08-24	Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer	CI

b06020509a1bcb5.Th-minmYSjPOwc_wRqWsERPXZdar7TmP1e4LkkAbrG8.IDLx3gj_G2K5paWCcpXVRSqiXabStFDukpZDvyR23j8Ua8vYI8s_QYaEoA~308914a47fc4d081fa542b3cdafbc3eb